CD274 and esophageal squamous cell carcinoma: Small sample sizes in the ESCC, PD-L1 CPS ≥ 10, and ESCC PD-L1 CPS ≥ 10 Japanese subgroups limit conclusions about the improved outcomes with pembrolizumab–chemotherapy versus placebo–chemotherapy.